Literature DB >> 6509007

Ocular changes in patients undergoing long-term desferrioxamine treatment.

G B Arden, B Wonke, C Kennedy, E R Huehns.   

Abstract

In a group of young patients with thalassaemia and iron overload treated by subcutaneous infusions of desferrioxamine we have found a number of minor alterations in retinal function. The incidence of such changes is not related to drug dosage or to ferritin level but to abnormality of the extended glucose tolerance test.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6509007      PMCID： PMC1040501          DOI： 10.1136/bjo.68.12.873

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


  14 in total

1.  New clinical test of retinal function based upon the standing potential of the eye.

Authors:  G B Arden; A Barrada; J H Kelsey
Journal:  Br J Ophthalmol       Date:  1962-08       Impact factor: 4.638

2.  A gold foil electrode: extending the horizons for clinical electroretinography.

Authors:  G B Arden; R M Carter; C Hogg; I M Siegel; S Margolis
Journal:  Invest Ophthalmol Vis Sci       Date:  1979-04       Impact factor: 4.799

3.  [Pathologic lens changes in experimental animals following continuous administration of high doses of Desferal].

Authors:  R Brückner; R Hess; H Keberle; C Pericin; J Tripod
Journal:  Helv Physiol Pharmacol Acta       Date:  1967

4.  Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.

Authors:  A V Hoffbrand; A Gorman; M Laulicht; M Garidi; J Economidou; P Georgipoulou; M A Hussain; D M Flynn
Journal:  Lancet       Date:  1979-05-05       Impact factor: 79.321

5.  An automated statis perimeter/adaptometer using light emitting diodes.

Authors:  W Ernst; D J Faulkner; C R Hogg; D J Powell; G B Arden
Journal:  Br J Ophthalmol       Date:  1983-07       Impact factor: 4.638

6.  A modified ERG technique and the results obtained in X-linked retinitis pigmentosa.

Authors:  G B Arden; R M Carter; C R Hogg; D J Powell; W J Ernst; G M Clover; A L Lyness; M P Quinlan
Journal:  Br J Ophthalmol       Date:  1983-07       Impact factor: 4.638

7.  Reassessment of the use of desferrioxamine B in iron overload.

Authors:  R D Propper; S B Shurin; D G Nathan
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

8.  An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload.

Authors:  G M Addison; M R Beamish; C N Hales; M Hodgkins; A Jacobs; P Llewellin
Journal:  J Clin Pathol       Date:  1972-04       Impact factor: 3.411

9.  Ocular toxicity of high-dose intravenous desferrioxamine.

Authors:  S C Davies; R E Marcus; J L Hungerford; M H Miller; G B Arden; E R Huehns
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

10.  Dialysis anaemia caused by subacute zinc toxicity.

Authors:  J J Petrie; P G Row
Journal:  Lancet       Date:  1977-06-04       Impact factor: 79.321
View more
  18 in total

1.  Macular vitelliform lesion in desferrioxamine-related retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman; Anastasios Anastasakis; Martin Lindeman
Journal:  Doc Ophthalmol       Date:  2010-06-09       Impact factor: 2.379

2.  Desferrioxamine (Desferal) and superoxide free radicals. Formation of an enzyme-damaging nitroxide.

Authors:  M J Davies; R Donkor; C A Dunster; C A Gee; S Jonas; R L Willson
Journal:  Biochem J       Date:  1987-09-15       Impact factor: 3.857

3.  Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.

Authors:  T Y Y Lai; G K Y Lee; W-M Chan; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

4.  Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.

Authors:  V De Sanctis; A Pinamonti; A Di Palma; M Sprocati; G Atti; M R Gamberini; C Vullo
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

5.  Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.

Authors:  Maria Dettoraki; Antonis Kattamis; Ioannis Ladas; Konstantinos Maragkos; Chryssanthi Koutsandrea; Klio Chatzistefanou; Konstantinos Laios; Dimitrios Brouzas; Marilita M Moschos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-30       Impact factor: 3.117

Review 6.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

7.  Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.

Authors:  S De Virgiliis; M Congia; M P Turco; F Frau; C Dessi; F Argiolu; R Sorcinelli; A Sitzia; A Cao
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

8.  Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.

Authors:  Rashi Taneja; Pankaj Malik; Mamta Sharma; Mahesh C Agarwal
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

9.  Ferric ion-induced lipid peroxidation in erythrocyte membranes: effects of phytic acid and butylated hydroxytoluene.

Authors:  K M Ko; D V Godin
Journal:  Mol Cell Biochem       Date:  1990-06-25       Impact factor: 3.396

Review 10.  Retinal abnormalities in β-thalassemia major.

Authors:  Devang L Bhoiwala; Joshua L Dunaief
Journal:  Surv Ophthalmol       Date:  2015-08-29       Impact factor: 6.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.